If you have been reading about 研究代号 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
== Ausstellungen == Seit 1976 wird Tichas Werk in Einzel- oder Sammelausstellungen gezeigt. In der DDR war er auf einer Anzahl wichtiger Ausstellungen vertreten, u. a. 1977/1978 und 1982/1983 auf der VIII. und IX. Kunstausstellung der DDR. 1990 war er an der Ausstellung Ambiente Berlin auf der Biennale di Venezia beteiligt.
=== Einzelausstellungen (unvollständig) === 1983: Berlin, Kleine Humboldtgalerie (Zeichnungen und Druckgrafik) 1993: Frankfurt a. M., Büchergilde Buchhandlung & Galerie 2007: Leipzig, Deutsches Buch- und Schriftmuseum (Buch und Grafik 1970 – 2006) 2008: Galleri Heike Arndt DK Berlin Soloausstellung 2009: Galleri Heike Arndt DK Kettinge Soloausstellung, Dänemark 2013: Kopenhagen, Arbeiter Museum Soloausstellung 2013: Born a. Darß und Berlin, Galerie Läkemaker 2014: Galleri Heike Arndt DK Berlin Soloausstellung "Selection" 2014: Hamburg, Büchergilde Hamburg (Grafik, illustrierte Bücher Zeichnungen) 2015: Born a. Darß, Galerie Läkemaker 2016: Jena, Kunstsammlung der Städtischen Museen Jena (Bilder, Zeichnungen, Objekte) 2016: Libnow, Galerie Läkemaker im Herrenhaus Libnow 2017: Born a. Darß und Berlin, Galerie Läkemaker 2019: Frankfurt a. M., Galerie Hanna Bekker vom Rath 2019: Ostseebad Wustrow, und Berlin, Galerie Läkemaker 2020: Rheinsberg, Kurt-Tucholsky-Literaturmuseum 2020: Schwerin, Schleswig-Holstein-Haus (Ausstellung zum 80. Geburtstag) 2020: Frankfurt a. M., Büchergilde Buchhandlung & Galerie (Zeichnungen zu Gedichten von Mascha Kaleko) 2021: Ostseebad Wustrow, Galerie Läkemaker (Hans Ticha Neue Bilder) 2022: Ostseebad Wustrow, Galerie Läkemaker (Ticha Werke auf Papier) 2023: Ostseebad Wustrow, Galerie Läkemaker (Ticha Materei Zeichnung Graphik) 2024: Leipzig, Museum für Druckkunst (Hans Ticha – Druckgrafiken 1966–2017) 2024: Frankfurt a.
M., Galerie Hanna Bekker vom Rath (Auf Papier) 2025: Quedlinburg, Museum Lyonel Feininger (Ticha | Kugel · Kegel · Körperkult) 2025: Berlin-Altglienicke, Galerie der Berliner Graphikpresse (Hans Ticha: Graphik & Plakate) 2025/26: Rostock, Kunsthalle Rostock (Hans Ticha Retrospektive) 2026: Ostseebad Wustrow, Galerie Läkemaker (Ticha Bilder Aquarelle Zeichnungen) 2026: Nürnberg, Neues Museum Nürnberg (Ticha, Retrospektive)
=== Allgemeines === Hans Ticha ist nicht nur im Bereich der Belletristik, sondern auch im Bereich der Kinder- und Jugendliteratur künstlerisch tätig. Im Zeitraum von 1973 bis 2007 illustrierte er 35 Bücher, die sich vor allem an junge Leser richten: zwanzig Bilderbücher, acht Kinderbücher, vier Jugendbücher und drei Lehr- bzw. Sachbücher. Außerdem steuerte Ticha jeweils eine Illustration zu drei Sammlungen mit Erzählungen bei, die jeweils von verschiedenen Künstlern – darunter auch Klaus Ensikat, Volker Pfüller und Elizabeth Shaw – bebildert wurden. Bis 1977 illustrierte er ausschließlich Kinder- bzw. Jugendbücher, während ab 1978 vor allem das Bilderbuch im Zentrum seines kinderliterarischen Schaffens stand. Mit Geschichten aus der Murkelei (1973) von Hans Fallada, Der kleine Häwelmann (1983) von Theodor Storm und Hans im Glück (1993) von den Brüdern Grimm illustrierte Ticha drei Klassiker der deutschsprachigen Kinder- und Jugendliteratur. Zu einer dreimaligen Zusammenarbeit kam es mit Peter Hacks, dessen Texte der Bilderbücher Das musikalische Nashorn (1978) und Die Baby-Herrschaft (1999) Ticha illustrierte. Außerdem illustrierte Ticha Hacks’ Gedichte Ich sehe was, was du nicht siehst und Die Sonne, die in der Gedichtsammlung Was sieht die Ringeltaube? (1978) erschienen sind.
Sources: de.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.